Therapy resistance and metastatic dissemination remain major challenges during cancer treatment. These are predominantly due to the presence of tumorigenic cells populations that determine the biology of cancer. Until now, resistant tumor cell populations have only been poorly characterized and effective mechanisms that can overcome those cell populations which evade targeted therapeutics have yet to be identified. At Tachyon, we are developing therapies that provide novel approaches to eradicating this population by targeting core tumorigenic mechanisms.